Try our beta test site
11 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) | Open Studies | cd22
Show Display Options
Rank Status Study
1 Recruiting Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
Conditions: Follicular Lymphoma;   ALL;   NHL;   Large Cell Lymphoma
Intervention: Biological: CD22-CAR
2 Recruiting CD22 Redirected Autologous T Cells for ALL
Conditions: B Cell Leukemias;   B Cell Lymphomas
Intervention: Biological: CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB
3 Recruiting A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
Conditions: Leukemia;   Lymphoma
Intervention: Biological: Anti-CD22-CAR-transduced T cells
4 Recruiting Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BAY1862864
5 Recruiting Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Stage III/IV Adult Diffuse Large Cell Lymphoma;   Stage III/IV Follicular Lymphoma;   Stage III/IV Mantle Cell Lymphoma
Intervention: Drug: Retroviral vector-transduced autologous T cells to express CD22-specific CARs
6 Recruiting CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
Conditions: Lymphoma;   Leukemia
Interventions: Drug: CMC-544;   Drug: Fludarabine;   Drug: Bendamustine;   Drug: Rituximab;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Thymoglobulin;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: G-CSF
7 Recruiting Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Drug: Cytarabine;   Biological: Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
8 Recruiting HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma
Conditions: Refractory B-Lineage Leukemia;   Relapsed B-Lineage Leukemia;   Refractory B-Lineage Lymphoma;   Relapsed B-Lineage Lymphoma
Intervention: Biological: DT2219ARL
9 Not yet recruiting Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Conditions: Childhood B Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Refractory Childhood Acute Lymphoblastic Leukemia
Interventions: Biological: Inotuzumab Ozogamicin;   Other: Laboratory Biomarker Analysis
10 Recruiting S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia
Conditions: Acute Leukemias of Ambiguous Lineage;   B-cell Adult Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma
Interventions: Drug: cyclophosphamide;   Drug: vincristine sulfate;   Drug: prednisone;   Biological: inotuzumab ozogamicin;   Other: laboratory biomarker analysis
11 Recruiting Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome (PC) Positive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML)
Condition: Leukemia
Interventions: Drug: Bosutinib;   Drug: Inotuzumab Ozogamicin;   Behavioral: Phone Call

Study has passed its completion date and status has not been verified in more than two years.